医学
身材矮小
荟萃分析
儿科
不利影响
人生长激素
发育不良
生长激素
内科学
内分泌学
激素
作者
Francesco Massart,Mario Miccoli,Angelo Baggiani,Silvano Bertelloni
出处
期刊:Pharmacogenomics
[Future Medicine]
日期:2015-11-01
卷期号:16 (17): 1965-1973
被引量:13
摘要
Hypochondroplasia (HCH) is a genetic skeletal dysplasia, characterized by rhizomelic short height (Ht) with facial dysmorphology and lumbar hyperlordosis. Albeit there are concerns that HCH children may not achieve optimal long-term outcome in response to recombinant human growth hormone (rhGH), anecdotal experiences suggested at least short-term Ht improvement. After thorough search of published studies, meta-analysis of rhGH use in HCH children was performed. In 113 HCH children, rhGH administration (median 0.25 mg/kg/week) progressively improved Ht pattern with 12 months catch-up growth (p < 0.0001). Then, Ht improvement resulted constant until 36 months (p < 0.0001), but stature remained subnormal. While bone age chronologically progressed, no serious adverse events were reported. In conclusion, our meta-analysis indicates that rhGH treatment progressively improved Ht outcome of HCH subjects.
科研通智能强力驱动
Strongly Powered by AbleSci AI